Oral vancomycin works against Clostridioides difficile (C. diff) because it is barely absorbed from the gut, which means the drug stays concentrated exactly where the infection lives: the colon. When you swallow a vancomycin capsule, almost all of it passes through your digestive tract intact, reaching stool concentrations thousands of times higher than what is needed to kill the bacterium. This quirk of poor absorption, which would be a fatal flaw for treating infections elsewhere in the body, turns out to be the ideal property for an intestinal pathogen. The story of how oral vancomycin became the preferred treatment, and why it is not without drawbacks, involves decades of shifting guidelines, head-to-head trials, and growing awareness of collateral damage to the gut microbiome.
The Drug Stays Where the Infection Is
Most antibiotics are designed to be absorbed into the bloodstream so they can reach infected tissues throughout the body. Vancomycin given intravenously does exactly that, and it is a workhorse for treating serious bloodstream infections caused by resistant bacteria like MRSA. But C. diff lives in the lumen of the large intestine, not in the blood. Intravenous vancomycin does a poor job reaching the colon in meaningful concentrations, which is why it is not used that way for C. diff.
Oral vancomycin flips the script. It is poorly absorbed in most patients, producing minimal or subtherapeutic levels in the blood.1PubMed. Significant absorption of oral vancomycin in a patient with clostridium difficile colitis and normal renal function Because so little crosses the intestinal wall, the drug accumulates in the gut. In one study of patients with suspected C. diff infection, fecal vancomycin levels increased in direct proportion to the dose given by mouth, confirming that what you swallow essentially ends up in the stool.2PubMed Central. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection Early reports from the late 1970s, when researchers first tried the approach, found mean stool vancomycin concentrations around 3,100 micrograms per gram, with very low blood levels.3Lancet. Oral vancomycin for antibiotic-associated pseudomembranous colitis That stool concentration dwarfs what is needed to inhibit C. diff growth, giving the drug a wide margin of effectiveness inside the colon.
How It Kills C. Diff
Vancomycin is a glycopeptide antibiotic that works by binding to components of the bacterial cell wall, preventing the bacterium from building and maintaining its outer structure. Without a functional cell wall, C. diff cannot survive and reproduce. Laboratory studies of C. diff strains that developed reduced susceptibility to vancomycin found that resistance was tied to mutations affecting the cell-wall target itself, confirming that this is the drug’s primary point of attack.4Journal of Antimicrobial Chemotherapy. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin Fortunately, clinically meaningful vancomycin resistance in C. diff remains rare; most isolates are still susceptible.5PubMed. Antimicrobial resistance in Clostridium difficile
Why It Replaced Metronidazole as First-Line Treatment
For years, metronidazole was the go-to antibiotic for C. diff, partly because it was cheap and widely available. Vancomycin was often reserved for severe cases or patients who did not respond. That changed in 2017, when the major U.S. infectious-disease societies updated their clinical practice guidelines and recommended vancomycin or fidaxomicin over metronidazole for an initial episode of C. diff infection, at a standard dose of 125 mg by mouth four times a day for ten days.6Clinical Infectious Diseases. SHEA/IDSA 2017 Clinical Practice Guideline Update for Clostridium difficile Infection in Adults and Children The 2017 update specifically removed metronidazole as a preferred option for initial, non-severe episodes.7PubMed. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection
The shift was driven by accumulating evidence that vancomycin outperformed metronidazole, especially when the infection was severe. A meta-analysis that stratified results by disease severity found that vancomycin produced significantly higher cure rates in severe C. diff: about 81% compared with 68% for metronidazole.8The Brazilian Journal of Infectious Diseases. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity A large multinational randomized trial similarly found clinical success in severe cases at roughly 79% for vancomycin versus 66% for metronidazole.9Clinical Infectious Diseases. Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials A more recent German multicenter cohort study confirmed the superiority of vancomycin across all severity levels, further reinforcing the guideline shift.10PubMed. Comparative effectiveness of vancomycin and metronidazole on event-free survival after initial infection in patients with Clostridioides difficile
Why the performance gap? Metronidazole, unlike vancomycin, is well absorbed from the gut. It reaches good blood levels, which is useful for infections elsewhere, but it means less drug remains in the colon to fight C. diff directly. Vancomycin’s poor absorption is its advantage here.
Vancomycin Versus Fidaxomicin
Fidaxomicin entered the picture as a newer, narrower-spectrum antibiotic for C. diff. In a pivotal phase 3 trial, fidaxomicin and vancomycin cured infections at similar rates: about 88% and 86%, respectively. But fidaxomicin had a clear edge in preventing the infection from coming back. Recurrence rates were roughly 15% with fidaxomicin compared with 25% with vancomycin.11PubMed. Fidaxomicin versus vancomycin for Clostridium difficile infection A meta-analysis of two pivotal trials confirmed the pattern: equivalent initial cure, but significantly fewer recurrences with fidaxomicin.12Clinical Infectious Diseases. Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
In patients who had already experienced a previous episode, the recurrence advantage was even more striking. One trial found that among those treated for a first recurrence, subsequent recurrence dropped from about 36% with vancomycin to 20% with fidaxomicin, a 44% relative reduction.13PubMed Central. Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin By 2020, updated U.S. guidelines began favoring fidaxomicin as the preferred agent over vancomycin when available.14PubMed Central. Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
So why is vancomycin still widely used if fidaxomicin has this recurrence advantage? Cost is a major factor. Fidaxomicin is considerably more expensive, and not all insurance plans cover it readily. Vancomycin remains effective for initial cure and is the standard fallback, particularly in hospitals and settings where formulary access is limited. In many parts of the world, oral vancomycin is still the first-line treatment simply because fidaxomicin is unavailable or unaffordable.
Severe and Fulminant Cases
When C. diff infection becomes severe or fulminant, meaning the patient has dangerously low blood pressure, organ dysfunction, or a paralyzed bowel (ileus), higher doses and alternative routes come into play. The concern with ileus is that a swallowed capsule may never reach the colon if the intestines are not moving contents forward. In these situations, guidelines recommend vancomycin delivered directly into the colon as a retention enema, typically 500 mg in 100 mL of saline every six hours.15PubMed. Vancomycin Enema in the Treatment of Clostridium difficile Infection Intravenous metronidazole is often added in these cases because it can reach the colon wall through the blood supply, complementing the locally delivered vancomycin.
Fulminant C. diff is a medical emergency. Patients who do not respond to aggressive antibiotic therapy may require surgery to remove part or all of the colon. The combination of oral and rectal vancomycin plus IV metronidazole is meant to buy time and, ideally, avoid that outcome.
The Collateral Damage to Your Gut Microbiome
The very property that makes oral vancomycin effective against C. diff, its concentration throughout the gut, also makes it destructive to the rest of the intestinal ecosystem. Vancomycin does not selectively target C. diff; it kills a broad range of gut bacteria, particularly those in the two dominant groups that make up a healthy microbiome. One study in humans found that vancomycin treatment virtually wiped out entire groups of beneficial bacteria, with most of the dominant genera from these groups becoming undetectable after treatment.16PubMed Central. Short- and long-term effects of oral vancomycin on the human intestinal microbiota
An animal study directly compared vancomycin and fidaxomicin on gut diversity. In mice inoculated with C. diff, seven days of vancomycin reduced the number of distinct microbial species to about 26, compared with roughly 134 after fidaxomicin, and 349 in normal mice.17PubMed. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin This is part of why fidaxomicin is associated with fewer recurrences: it does not strip the microbiome as aggressively, leaving beneficial bacteria in place to resist C. diff recolonization.
This microbiome disruption matters because a depleted gut flora is precisely what allows C. diff to take hold in the first place. Healthy gut bacteria compete with C. diff for nutrients and space, and they produce short-chain fatty acids and other compounds that suppress C. diff growth. Killing those competitors with vancomycin can set up a vicious cycle in which treatment for one episode creates the conditions for the next.
Recurrent Infection and Tapered Dosing
Recurrence is the great frustration of C. diff management. Roughly one in four patients who respond to initial treatment will have the infection come back, and the risk rises with each subsequent episode. To break this cycle, clinicians often prescribe a tapered and pulsed vancomycin regimen for recurrent infections. Instead of stopping abruptly after ten days, the dose is gradually reduced over several weeks, then given every other day or every third day for a further period. The idea is to suppress C. diff while giving the microbiome time to recover between doses.
The evidence that pulsed dosing actually clears C. diff spores, however, is less encouraging than the clinical tradition might suggest. A mouse study found that pulse dosing was not effective at maintaining suppression of C. diff; vegetative bacteria regrew between pulses when vancomycin levels dropped to undetectable levels, and spores were not cleared.18PubMed Central. Pulsed dosing and extended daily dosing of oral vancomycin do not facilitate clearance of Clostridioides difficile colonization in mice Whether the same dynamics play out in humans is not fully settled, but the finding underscores that tapered-pulsed regimens may work more by allowing microbial recovery than by eradicating spores.
The Risk of Breeding Vancomycin-Resistant Enterococci
One of the most serious downsides of oral vancomycin is that it promotes the emergence of vancomycin-resistant enterococci, or VRE, in the gut. Enterococci are bacteria that naturally live in the intestines. When exposed to prolonged, high concentrations of vancomycin, resistant strains can be selected and multiply. Because oral vancomycin reaches much higher gut concentrations than the intravenous form, it poses a substantially greater risk for this particular problem.
A time-series analysis found a significant association between oral vancomycin use and VRE acquisition, attributing this to the high gut concentrations and the drug’s tendency to form aggregates with intestinal mucus that prolong its exposure in the gastrointestinal tract.19PubMed Central. Oral vancomycin use and incidence of vancomycin-resistant enterococci: time-series analysis A separate study specifically looking at patients treated for C. diff found that oral vancomycin as a main therapy was independently associated with roughly a fourfold increased odds of later acquiring VRE.20PubMed. Usage of oral vancomycin for acute Clostridioides difficile infection (CDI) resulting in later acquisitions of vancomycin-resistant enterococci (VRE)
A randomized controlled trial of oral vancomycin in patients who were colonized with C. diff (but not actively sick) drove this point home: vancomycin did not permanently clear C. diff colonization, and it was associated with VRE colonization and environmental contamination.21American Society for Microbiology. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients This is one reason clinicians are cautious about using oral vancomycin outside of confirmed symptomatic infection. Treating people who simply carry C. diff without symptoms does more harm than good.
When Absorption Becomes a Problem
The assumption that oral vancomycin stays in the gut is generally true but not absolute. In patients with severe colitis that damages the intestinal lining, the drug can cross into the bloodstream in surprising amounts. A case report documented a patient with severe colitis and kidney failure whose blood vancomycin levels climbed to over 30 micrograms per milliliter after oral dosing, a level that would normally require intravenous administration to achieve. The estimated bioavailability in that patient was over 54%, meaning more than half the oral dose was being absorbed, likely because the inflamed, ulcerated colon was no longer an effective barrier.22PubMed. An extremely high bioavailability of orally administered vancomycin in a patient with severe colitis and renal insufficiency
For patients with normal kidneys, excess absorbed vancomycin is cleared without much trouble. But in patients with kidney impairment, the drug can accumulate to toxic levels and potentially cause hearing damage or kidney injury. This means that in the very patients who are sickest from C. diff, the ones with severe colitis receiving high-dose oral vancomycin, monitoring blood levels may be warranted, especially if their kidneys are not functioning well.
Adjunctive Therapies That Pair With Vancomycin
Because vancomycin alone does not solve the recurrence problem, clinicians increasingly combine it with other strategies. Bezlotoxumab is a monoclonal antibody given as a single intravenous infusion during antibiotic treatment. It targets toxin B, one of the two main toxins C. diff produces to damage the colon. In two large randomized trials, recurrence rates dropped from about 27% with placebo to roughly 16-17% when bezlotoxumab was added to standard antibiotic therapy.23New England Journal of Medicine. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection It does not replace the antibiotic but substantially reduces the chance of relapse, particularly in patients at high risk for recurrence.
Fecal microbiota transplantation, or FMT, takes a more direct approach to the underlying problem. By introducing stool from a healthy donor into the patient’s gut, FMT restores the diverse microbial community that vancomycin destroys. In a randomized trial of patients with first or second episodes, FMT after a course of oral vancomycin produced resolution in 90% of patients, compared with 33% who received vancomycin followed by placebo, a striking absolute risk reduction of 57%.24The Lancet Gastroenterology & Hepatology. Faecal microbiota transplantation versus placebo after oral vancomycin for first or second Clostridioides difficile infection (EarlyFMT) Standardized microbiome-based therapies derived from donor stool have now been approved by the FDA for recurrent C. diff, adding another tool beyond repeated vancomycin courses.
Children Are Treated Differently
Pediatric guidelines have not mirrored the adult shift away from metronidazole as closely. The American Academy of Pediatrics still recommends oral metronidazole as first-line treatment for an initial or first-recurrent episode of mild-to-moderate C. diff infection in children. Oral vancomycin is reserved for severe pediatric cases and for second recurrences.25PubMed Central. Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value The reasoning reflects the different epidemiology of C. diff in children, where severe disease is less common, and the desire to limit vancomycin exposure given concerns about antibiotic resistance. This is one of those areas where age matters: what is standard care for an adult with C. diff is not automatically appropriate for a child.
Compounding and Practical Quirks
Oral vancomycin is available as branded capsules, but these can be expensive. Many hospital and outpatient pharmacies compound an oral liquid solution from vancomycin powder intended for intravenous use. This is a well-established practice and substantially cheaper. Stability testing has shown that both formulations, whether prepared from the pure ingredient or the commercial injectable product, remain chemically and microbiologically stable for up to 90 days when refrigerated, and up to 30 days at room temperature.26PubMed Central. Analysis of the Stability of Compounded Vancomycin Hydrochloride Oral Solution: A Comparison Between Formulations Prepared Using a Commercial Product and Using the Pure Active Ingredient If you are prescribed a compounded oral vancomycin solution, keeping it in the refrigerator is the standard recommendation for longer-term storage.
The taste of the compounded liquid is famously unpleasant, bitter enough that pharmacies often add flavoring. Some patients find it easier to mix the solution into a small amount of a flavored drink. This is a minor point but a practical one, because patients who cannot tolerate the taste may not complete their full course, and incomplete treatment invites recurrence.